Physician profile
Linan Bo
NPI 1750924247
$1,559.64
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $445 · 2022: $826 · 2023: $254 · 2024: $35.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $289.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $302.65 | 2021-2023 | Ztlido |
| Grt US Holding, INC. | $197.90 | 2021-2022 | |
| Lundbeck LLC | $192.59 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.40 | 2021-2022 | |
| Forte Bio-Pharma LLC | $126.43 | 2022-2024 | Prolate, Nalocet |
| Lilly USA, LLC | $120.00 | 2021 | |
| Collegium Pharmaceutical, INC. | $118.49 | 2021-2023 | Xtampza |
| Biohaven Pharmaceutical Holding Company LTD. | $77.56 | 2022 | |
| Abbvie INC. | $64.69 | 2022-2024 | |
| Si-Bone, INC. | $58.98 | 2021-2023 | |
| Amgen INC. | $32.95 | 2022 | |
| Arbor Pharmaceuticals, INC. | $29.74 | 2021-2022 | |
| Medtronic, INC. | $29.09 | 2023 | Intellis Adaptivestim, Synchromedii |
| Merck Sharp & Dohme LLC | $24.06 | 2022 | |
| Biodelivery Sciences International, INC. | $23.42 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linan Bo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.